SLNO:NASDAQSoleno Therapeutics, Inc. Analysis

Soleno Therapeutics (SLNO) trades at $52.82, just above its 20‑day SMA of $51.99 and well above the 50‑day SMA of $42.46, but still below the 200‑day SMA of $54.40, indicating a short‑term bullish bias within a longer‑term neutral framework. The RSI of 77 places the stock in overbought territory, while the MACD line sits below its signal line, generating a bearish histogram – a classic divergence that warns of near‑term downside pressure. Valuation metrics are stark: a trailing PE of 135× dwarfs the industry average of 25×, and the DCF‑derived fair value of $17.30 is less than one‑third of the current price, flagging significant overvaluation. Despite a solid cash balance of $305 M and positive free cash flow, the company carries a high debt‑to‑equity ratio of 11.7 and zero revenue growth, limiting upside. Volatility is extreme at 93 % over the past 30 days, and trading volume is on a downtrend, suggesting thinning liquidity. Compounding these technical and valuation concerns, a securities‑fraud class‑action lawsuit alleging misstatements about its Phase 3 trial and post‑launch safety has surfaced, adding legal headwinds.
Given the confluence of overbought momentum, bearish MACD, inflated multiples, and material litigation risk, the near‑term outlook tilts negative, though the company’s high gross margin (98 %) and cash runway provide a cushion. Investors should treat SLNO as overvalued and prioritize risk mitigation, with a bias toward reducing exposure while monitoring any regulatory or legal resolution that could alter the risk‑reward profile.